期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

乳腺癌“液体活检”:血清标志物与循环肿瘤细胞的检测 被引量：4

Liquid biopsy in breast cancer: serum biomarker and circulating tumor cell detection
下载PDF
导出
摘要 乳腺癌疗效和预后指标的检测可以帮助我们进行个体化治疗。循环肿瘤细胞(Circulating tumor cells,CTCs)的检测为我们提供了乳腺癌的实时"液体活检",可以预测乳腺癌患者的预后;进行乳腺癌化疗、内分泌等治疗前后CTCs变化情况的监测,预测治疗的疗效;进一步研究CTCs的基因表型,明确其生物学行为,从而提高乳腺癌的治疗效果,降低其死亡率。 Detection of efficacy and prognosis predictive factors in breast cancer can help us with individualized treatment. Circulating tumor cells （CTCs） test provides us a real-time ＂liquid biopsy＂ in breast cancer, which can predict the prognosis of breast cancer patients, monitor the CTCs number changes before and after chemotherapy or endocrine therapy, and predict the treatment efficacy. The further study of CTCs gene phenotype and its biological behavior can improve the therapeutic effect of breast cancer, thereby reducing the breast cancer mortality.
作者 陈小松 沈坤炜
机构地区 上海交通大学医学院附属瑞金医院乳腺疾病诊治中心
出处 《分子诊断与治疗杂志》 2012年第6期410-414,共5页 Journal of Molecular Diagnostics and Therapy
基金 国家自然科学基金项目(编号:81202087 81172520) 上海市教育委员会重点学科建设项目(编号:J50208)
关键词 乳腺癌 循环肿瘤细胞 血清标志物 活检 个体化治疗 Breast cancer Circulating tumor cell Serum biomarker Biopsy Individualized therapy
分类号 R737.9 [医药卫生—肿瘤]
  • 相关文献

参考文献22

  • 1Goldhirsch A, Wood W C, Coates A S, et al. Strategies for subtypes--dealing with the diversity of breast cancer: highlights of the St. Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011 [J]. Ann Oncol, 2011, 22(8): 1736-1747.
  • 2Danova M, Delfanti S, Manzoni M, et al. Tissue and soluble biomarkers in breast cancer and their applications: ready to use[J]. J Natl Cancer lnst Monogr, 2011,2011(43): 75-78.
  • 3Harris L, Fritsche H, Mennel R, et al. American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer[J]. J Clin Oncol, 2007, 25(33): 5287-5312.
  • 4Gianni L, Romieu G, Lichinitser M, et al. First results of AVEREL, a randomized phase III trial to evaluate bevacizumab (BEV) in combination with trastuzumab (H)+ docetaxel (DOC) as first-line therapy for HER2-positive locally recurrent/metastatic breast cancer (LR/mBC)[C]SABCS, 201 l, Abstract: $4-8.
  • 5Paterlini-Brechot P, Benali N L. Circulating tumor cells (CTC) detection: clinical impact and future directions[J]. Cancer Lett, 2007, 253(2): 180-204.
  • 6Pantel K, Alix-Panabires C. Circulating tumour cells in cancer patients: challenges and perspectives[J]. Trends Mol Med, 2010, 16(9): 398-406.
  • 7Alunni-Fabbroni M, Sandri M T. Circulating tumour ceils in clinical practice: Methods of detection and possible characterization[J]. Methods, 2010, 50(4): 289-297.
  • 8Cristofanilli M, Budd G T, Ellis M J, et al. Circulating tumor cells, disease progression and survival in metastatic breast cancer[J]. N Engl J Med, 2004, 351(8): 781-791.
  • 9Pierga J Y, Hajage D, Bachelot T, et al. High independent prognostic and predictive value of circulating tumor cells compared with serum tumor markers in a large prospective trial in first-line chemotherapy for metastatic breast cancer patients[J]. Ann Oncol, 2012, 23(3): 618-624.
  • 10Ignatiadis M, Xenidis N, Perraki M, et al. Different prognostic value of cytokeratin-19 mRNA positive circulating tumor cells according to estrogen receptor and HER2 status in early- stage breast cancer[J]. J Clin Oncol, 2007, 25(33): 5194-5202.

同被引文献56

  • 1Gold B,Cankovic M,Furtado L V,et al.Do Circulating Tumor cells,Exosomes,and Circulating Tumor Nucleic Acids Have Cinical Utility.A Report of the Association for Molecular Pathology[J]J Molecuar biagnost,2015,17(3):209-224.
  • 2Les acides nucl′eiques du plasma sanguin chez l’homme[J].C R Hebd Seances Acad Sci(Paris),1948,142(3):241-243.
  • 3paricio S A,aldas C C.The Implications of Clonal Genome Evolution for Cancer Medicine[J].N Engl J Med,2013,368(9):842-851.
  • 4Newman A M,Bratman S V,To J,et al.An ultrasensitive method for quantitating circulating tumor DNA with broad patient coverage[J].Nat Med,2014,20(5):552-558.
  • 5Madhavan D,Wallwiener M,Bents K,et al.Plasma DNA integrity as a biomarker for primary and metastatic breast cancer and potential marker for early diagnosis[J].Breast Cancer Res Treat,2014,146(1):163-174.
  • 6Bettegowda C,Sausen M,Leary R J,et al.Detection of Circulating Tumor DNA in Early-and Late-Stage Human Malignancies[J].Sci Translat Med,2014,6(224),224.
  • 7Grutzmann R,Molnar B,Pilarsky C,et al.Sensitive detection of colorectal cancer in peripheral blood by septin 9 DNA methylation assay[J].PLo S One,2008,3(11):e3759.
  • 8Warren J D,Xiong W,Bunker A M,et al.Septin 9 methylated DNA is a sensitive and specific blood test for colorectal cancer[J].BMC Med,2011,9(24):133.
  • 9Church T R,Wandell M,Lofton-Day C,et al.Prospective evaluation of methylated SEPT9 in plasma for detection of asymptomatic colorectal cancer[J].Gut,2014,63(2):317-325.
  • 10Kim K,Shin D G,Park M K,et al.Circulating cell-free DNA as a promising biomarker in patients with gastric cancer:diagnostic validity and significant reduction of cf DNA after surgical resection[J].Ann Surg Treat Res,2014,83(3):136-142.

引证文献4

二级引证文献11

分子诊断与治疗杂志
2012年 第6期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部